NFKB1 and serum lipopolysaccharide activity: The therapeutic potential of strategies to inhibit NF-κB is evident from the demonstration that NF-κB inhibition decreases injury in nonseptic ALI models, including pulmonary [6] and systemic reperfusion, and endotoxemia [7].